EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokollOpen Access · CC BY 4.0

Efficacy of celecoxib add-on treatment for immuno-metabolic depression: Protocol of the INFLAMED double-blind placebo-controlled randomized controlled trial

J C Zwiep, P M Bet, D Rhebergen, M T Nurmohamed, C H Vinkers, B W J H Penninx, Y Milaneschi, F Lamers

Brain, Behavior, & Immunity - Health · 2023-02 · 27 · 100585

DOI: 10.1016/j.bbih.2022.100585 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Brain, Behavior, & Immunity - Health, 2023-02. Verfasst von J C Zwiep und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Amsterdam UMC, Vrije Universiteit, De Boelelaan 1117, 1118, 1081 HV, Amsterdam, the Netherlands. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hersenstichting.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction: As the role of (neuro)inflammation in depression pathophysiology is emerging, augmentation of antidepressant treatments with anti-inflammatory drugs have shown beneficial results, but not consistently across all studies. Inconsistencies may be due to depression biological and clinical heterogeneity. Immuno-Metabolic Depression (IMD) has been put forward as a form of depression characterized by the clustering of low-grade inflammation, metabolic dysregulations and atypical, energy-related symptoms (overeating, weight gain, hypersomnia, fatigue and leaden paralysis). IMD features are present in ∼30% of patients with Major Depressive Disorder (MDD). By selecting these specific patients, directly targeting inflammation may reduce depressive symptoms. Methods: and analysis INFLAMED is a double-blind randomized controlled trial. 140 MDD patients with IMD characteristics (MDD with Inventory of Depressive Symptomatology (IDS) ≥ 26, IDS atypical, energy related symptoms ≥6, C-Reactive Protein (CRP) > 1 mg/L) will receive either 400 mg celecoxib per day or matching placebo for a period of 12 weeks. Biological, physical and interview data will be collected after 2, 6 and 12 weeks of starting the intervention. Questionnaires will be sent out bi-weekly during the study period. The main study outcome is the IDS (30-item self-report) total score during 12-week follow-up. Secondary study outcomes include response, remission, adverse side effects, symptom profiles (atypical, energy-related symptoms), fatigue, food craving, sleep, anxiety symptoms, functioning, pain, and optionally, microbiome composition. Explorative analyses will be performed on the role of CRP, IL-6, TNF-α, cholesterol, triglycerides, glucose, BMI, waist and hip circumference. Ethics and dissemination: This protocol has been approved by the Medical Ethics Review Board of the Amsterdam UMC, location VUmc (2022.0015) on 2-6-2022, as well as by the competent authority in The Netherlands: CCMO, on 3-8-2022. Registration details: Trail registration numbers NCT05415397, EudraCT 2021-003850-21.

Schlagwörter

Stichwörter der Autor:innen

Anti-inflammatory medicationCelecoxibInflammationMajor depressive disorderMetabolismRandomized controlled trialTreatment

Autor:innen und Institutionen

  • Department of Psychiatry, Amsterdam UMC, Vrije Universiteit, De Boelelaan 1117, 1118, 1081 HV, Amsterdam, the Netherlands.
  • Amsterdam Public Health, Mental Health Program, Amsterdam, the Netherlands.
  • Department of Clinical Pharmacology and Pharmacy, Amsterdam UMC, Vrije Universiteit, De Boelelaan 1117, 1118, 1081 HV, Amsterdam, the Netherlands.
  • GGZ Centraal Mental Health Care, Department of Research, Amersfoort, the Netherlands.
  • Department of Rheumatology, Amsterdam UMC, Vrije Universiteit, De Boelelaan 1117, 1118, 1081 HV, Amsterdam, the Netherlands.
  • Amsterdam Neuroscience, Mood, Anxiety, Psychosis, Sleep & Stress Program, Amsterdam, the Netherlands.

Förderung

  • Hersenstichting

Zitieren

APA

Zwiep, J. C., Bet, P. M., Rhebergen, D., Nurmohamed, M. T., Vinkers, C. H., Penninx, B. W. J. H., Milaneschi, Y., & Lamers, F. (2023). Efficacy of celecoxib add-on treatment for immuno-metabolic depression: Protocol of the INFLAMED double-blind placebo-controlled randomized controlled trial. Brain, Behavior, & Immunity - Health, 27, 100585. https://doi.org/10.1016/j.bbih.2022.100585

Vancouver

Zwiep JC, Bet PM, Rhebergen D, Nurmohamed MT, Vinkers CH, Penninx BWJH, et al. Efficacy of celecoxib add-on treatment for immuno-metabolic depression: Protocol of the INFLAMED double-blind placebo-controlled randomized controlled trial. Brain, Behavior, & Immunity - Health. 2023;27:100585. doi:10.1016/j.bbih.2022.100585

BibTeX
@article{Zwiep2023,
  author = {Zwiep, J C and Bet, P M and Rhebergen, D and Nurmohamed, M T and Vinkers, C H and Penninx, B W J H and Milaneschi, Y and Lamers, F},
  title = {Efficacy of celecoxib add-on treatment for immuno-metabolic depression: Protocol of the INFLAMED double-blind placebo-controlled randomized controlled trial},
  journal = {Brain, Behavior, & Immunity - Health},
  year = {2023},
  volume = {27},
  pages = {100585},
  doi = {10.1016/j.bbih.2022.100585}
}
Kostenlos starten →